In the past year, Japan’s life sciences and health care sector has been recalibrating, a process catalyzed by ongoing concern over “drug lag” and “drug loss,” as well as the desire to restore Japan’s attractiveness as a priority market for pharmaceutical and biotechnology innovation: a trend we predict will continue in 2026. Japan will likely continue to see increasingly coordinated initiatives among the Ministry of Health, Labour and Welfare (MHLW), the Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Economy, Trade and Industry (METI), and the Cabinet Office.

Following the February 2026 electoral win of Prime Minister Sanae Takaichi, leader of the Liberal Democratic Party (LDP), we predict several meaningful effects on the Japanese life sciences sector, including continued, strengthened governmental support for research and innovation in biotechnology, genomics, drug discovery, and advanced medicine. Under a stable LDP administration, we may see regulatory frameworks streamlined further to encourage innovation in the sector, and life sciences companies may find Japan more attractive for clinical development and partnerships.

From a transactional perspective, we anticipate increased private equity investment, strategic consolidation by domestic pharmaceutical companies, and rising regional deal activity. Regulatory modernization and global strategic positioning may lead to more dynamic and interconnected Japanese M&A and investment activity. This trend could be enhanced by the new government’s stronger emphasis on positioning Japan as a global leader in advanced science and technology, including addressing competition in the APAC region, especially with China.

We further foresee Japan encouraging earlier inclusion of the country in global development programs, especially in oncology, rare diseases, and advanced therapies, such as regenerative medicine, cell therapies, and gene therapies. We do not anticipate change to Japan’s conservative approach, nor to its high standards for safety and evidentiary data; however, there may be greater openness to regulatory dialogue and pragmatic problem solving where “unmet medical need” can be clearly demonstrated.

Companies entering the Japanese market will continue to need effective strategies to address pricing controls, periodic National Health Insurance (NHI) price revisions, and post-launch scrutiny, including real-world data, post-marketing studies, and digital health inputs. However, they should also be able to take advantage of the increased regulatory focus on innovation and selective flexibility for products that deliver clinical and societal benefit.

In the IP arena, we expect ongoing refinements to patent practice, enforcement, and policy, including greater emphasis on de facto patent linkage, particularly in respect of biological and complex products. We are also seeing a renewed focus on supply chain resilience and on domestic availability in the light of the lessons from the pandemic and ongoing geopolitical change and uncertainty.

We advise companies in the Japanese life sciences and health care sector in 2026 to commit to early, integrated, and long-term engagement, rather than risking seeking late or transactional market entry.